<DOC>
	<DOCNO>NCT00549705</DOCNO>
	<brief_summary>Registry Hospitalized patient Brigham Women 's Hospital treat Fondaparinux</brief_summary>
	<brief_title>Registry Hospitalized Patients Treated With Fondaparinux</brief_title>
	<detailed_description>The use antithrombotic agent hospital mainstay therapy treatment prophylaxis venous thromboembolism ( VTE ) acute coronary syndrome ( ACS ) . Concern administration heparin risk adverse sequela lead development newer , longer-acting agent . Fondaparinux offer daily administration extremely small risk develop heparin induce thrombocytopenia . Recent data demonstrate efficacy safety Fondaparinux VTE ACS , expand use clinical practice . We aim : 1 ) determine Fondaparinux use `` real life '' clinical setting , tertiary-care academic medical center ( BWH ) , 2 ) ass associate clinical outcome 90 day initiation Fondaparinux .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>BWH hospitalize patient receive Fondaparinux</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Anticoagulation</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Clotting</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
</DOC>